Omniflow II for Vascular Access is a Biosynthetic Vascular Prosthesis indicated when a viable AV fistula cannot be constructed. Clinical evidence shows that Omniflow II is superior to synthetic grafts.
High Primary Patency means more time to the first revision
High Secondary Patency means more time after first revision
Low infection rate means more time without complications
Ease of handling
Bio Nova International Pty Ltd | Biosynthetic Tissue Manufacturer
Bio Nova International is the leading biosynthetic tissue manufacturer in the world, specialising in collagen based medical devices.
Bio Nova is fully accredited to ISO13485 as a medical device manufacturer and produces replacement blood vessels (vascular prostheses or vascular grafts) for surgical bypass of diseased peripheral arteries to avoid amputation and providing an arteriovenous access (AV access) for haemodialysis patients.
Bio Nova develops products using its proprietary technology, conducts the necessary validation and approvals, manufactures and markets the products and sells to distribution partners.
Based in Melbourne, Australia, the manufacturing operations have purpose-designed clean room facilities for processing and sterilisation of medical devices.
The Company's research and testing laboratories are equipped to conduct many specialised evaluations on the physico-chemical characteristics of graft materials.
Bio Nova is dedicated to patient care through the application of creative high technology to designing, engineering and manufacturing quality.
Bio Nova has established distribution partners in over 30 countries - including most of Europe, Australia, Canada, parts of Latin America and Asia.